Statistical Evidence for High-penetrance MODY-causing Genes in a Large Population-based Cohort

Overview

Journal Endocrinol Diabetes Metab

Specialty Endocrinology

Date 2022 Oct 8

PMID 36208030

Authors

Liana K Billings

Zhuqing Shi

W Kyle Resurreccion

Chi-Hsiung Wang

Jun Wei

Toni I Pollin

Miriam S Udler

Jianfeng Xu

Affiliations

Soon will be listed here.

Abstract

Aims: Numerous genes have been proposed as causal for maturity-onset diabetes of the young (MODY). Scoring systems to annotate mutation pathogenicity have been widely used; however, statistical evidence for being a highly penetrant MODY gene has not been well-established.

Methods: Participants were from the UK Biobank with whole-exome sequencing data, including 14,622 with and 185,509 without diagnosis of diabetes. Pathogenic/likely pathogenic (P/LP) mutations in 14 reported and 3 possible MODY genes were annotated using American College of Medical Genetics criteria. Evidence for being a high-penetrant MODY gene used two statistical criteria: frequency of aggregate P/LP mutations in each gene are (1) significantly more common in participants with a diagnosis of diabetes than without using the SKAT-O (p < .05) and (2) lower than the maximum credible frequency in the general population.

Results: Among the 17 genes, 6 (GCK, HNF1A, HNF4A, NEUROD1, KCNJ11 and HNF1B) met both criteria, 7 (ABCC8, KLF11, RFX6, PCBD1, WFS1, INS and PDX1) met only one criterion, and the remaining 4 (CEL, BLK, APPL1 and PAX4) failed both criteria, and were classified as 'consistent', 'inconclusive' and 'inconsistent' for being highly penetrant diabetes genes, respectively. Diabetes participants with mutations in the 'consistent' genes had clinical presentations that were most consistent with MODY. In contrast, the 'inconclusive' and 'inconsistent' genes did not differ clinically from non-carriers in diabetes-related characteristics.

Conclusions: Data from a large population-based study provided novel statistical evidence to identify 6 MODY genes as consistent with being highly penetrant. These results have potential implications for interpreting genetic testing results and clinical diagnosis of MODY.

Citing Articles

Genetic Structure of Hereditary Forms of Diabetes Mellitus in Russia.

Minniakhmetov I, Khusainova R, Laptev D, Yalaev B, Karpova Y, Deev R Int J Mol Sci. 2025; 26(2).

PMID: 39859454 PMC: 11766241. DOI: 10.3390/ijms26020740.

haploinsufficiency in a mother-daughter pair with young-onset diabetes with and without neonatal hypoglycemia.

Uehara E, Shimura N, Matsubara K, Kageyama I, Yorifuji T, Fukami M Clin Pediatr Endocrinol. 2025; 34(1):66-69.

PMID: 39777127 PMC: 11701015. DOI: 10.1297/cpe.2024-0038.

MODY Only Monogenic? A Narrative Review of the Rare and Low-Penetrant Variants.

Hasballa I, Maggi D Int J Mol Sci. 2024; 25(16).

PMID: 39201476 PMC: 11354648. DOI: 10.3390/ijms25168790.

Update to the essential genomic nursing competencies and outcome indicators.

Calzone K, Stokes L, Peterson C, Badzek L J Nurs Scholarsh. 2024; 56(5):729-741.

PMID: 38797885 PMC: 11530310. DOI: 10.1111/jnu.12993.

From glucose sensing to exocytosis: takes from maturity onset diabetes of the young.

Samadli S, Zhou Q, Zheng B, Gu W, Zhang A Front Endocrinol (Lausanne). 2023; 14:1188301.

PMID: 37255971 PMC: 10226665. DOI: 10.3389/fendo.2023.1188301.

References

Gloyn A, Siddiqui J, Ellard S . Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2006; 27(3):220-31. DOI: 10.1002/humu.20292. View

Patel K, Kettunen J, Laakso M, Stancakova A, Laver T, Colclough K . Heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance. Nat Commun. 2017; 8(1):888. PMC: 5638866. DOI: 10.1038/s41467-017-00895-9. View

Rehm H, Berg J, Brooks L, Bustamante C, Evans J, Landrum M . ClinGen--the Clinical Genome Resource. N Engl J Med. 2015; 372(23):2235-42. PMC: 4474187. DOI: 10.1056/NEJMsr1406261. View

Barrett T, Bundey S, Macleod A . Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet. 1995; 346(8988):1458-63. DOI: 10.1016/s0140-6736(95)92473-6. View

Cummings B, Karczewski K, Kosmicki J, Seaby E, Watts N, Singer-Berk M . Transcript expression-aware annotation improves rare variant interpretation. Nature. 2020; 581(7809):452-458. PMC: 7334198. DOI: 10.1038/s41586-020-2329-2. View

Borowiec M, Liew C, Thompson R, Boonyasrisawat W, Hu J, Mlynarski W . Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A. 2009; 106(34):14460-5. PMC: 2732833. DOI: 10.1073/pnas.0906474106. View

Bonnycastle L, Chines P, Hara T, Huyghe J, Swift A, Heikinheimo P . Autosomal dominant diabetes arising from a Wolfram syndrome 1 mutation. Diabetes. 2013; 62(11):3943-50. PMC: 3806620. DOI: 10.2337/db13-0571. View

Stoy J, Edghill E, Flanagan S, Ye H, Paz V, Pluzhnikov A . Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A. 2007; 104(38):15040-4. PMC: 1986609. DOI: 10.1073/pnas.0707291104. View

Ellard S, Colclough K, Patel K, Hattersley A . Prediction algorithms: pitfalls in interpreting genetic variants of autosomal dominant monogenic diabetes. J Clin Invest. 2019; 130(1):14-16. PMC: 6934181. DOI: 10.1172/JCI133516. View

10.

Flannick J, Beer N, Bick A, Agarwala V, Molnes J, Gupta N . Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet. 2013; 45(11):1380-5. PMC: 4051627. DOI: 10.1038/ng.2794. View

11.

Simaite D, Kofent J, Gong M, Ruschendorf F, Jia S, Arn P . Recessive mutations in PCBD1 cause a new type of early-onset diabetes. Diabetes. 2014; 63(10):3557-64. DOI: 10.2337/db13-1784. View

12.

Zhang H, Colclough K, Gloyn A, Pollin T . Monogenic diabetes: a gateway to precision medicine in diabetes. J Clin Invest. 2021; 131(3). PMC: 7843214. DOI: 10.1172/JCI142244. View

13.

Whiffin N, Minikel E, Walsh R, ODonnell-Luria A, Karczewski K, Ing A . Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med. 2017; 19(10):1151-1158. PMC: 5563454. DOI: 10.1038/gim.2017.26. View

14.

Flannick J, Mercader J, Fuchsberger C, Udler M, Mahajan A, Wessel J . Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. Nature. 2019; 570(7759):71-76. PMC: 6699738. DOI: 10.1038/s41586-019-1231-2. View

15.

Malecki M, Jhala U, Antonellis A, Fields L, Doria A, Orban T . Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet. 1999; 23(3):323-8. DOI: 10.1038/15500. View

16.

Molven A, Ringdal M, Nordbo A, Raeder H, Stoy J, Lipkind G . Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008; 57(4):1131-5. DOI: 10.2337/db07-1467. View

17.

Yilmaz Aydogan H, Gul N, Demirci D, Mutlu U, Gulfidan G, Arga K . Precision Diagnosis of Maturity-Onset Diabetes of the Young with Next-Generation Sequencing: Findings from the MODY-IST Study in Adult Patients. OMICS. 2022; 26(4):218-235. DOI: 10.1089/omi.2022.0006. View

18.

Goodrich J, Singer-Berk M, Son R, Sveden A, Wood J, England E . Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. Nat Commun. 2021; 12(1):3505. PMC: 8190084. DOI: 10.1038/s41467-021-23556-4. View

19.

Plengvidhya N, Kooptiwut S, Songtawee N, Doi A, Furuta H, Nishi M . PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab. 2007; 92(7):2821-6. DOI: 10.1210/jc.2006-1927. View

20.

Shields B, McDonald T, Ellard S, Campbell M, Hyde C, Hattersley A . The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia. 2012; 55(5):1265-72. PMC: 3328676. DOI: 10.1007/s00125-011-2418-8. View